Lineage Cell Therapeutics (LCTX)

P/S ratio as of November 2024 (TTM): 27.0

According to Lineage Cell Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.50. At the end of 2024 the company had a P/S ratio of 30.4.

P/S ratio history for Lineage Cell Therapeutics from 2001 to 2024

PS ratio at the end of each year

Year	P/S ratio	Change
2024	30.4	42.76%
2023	21.3	57.65%
2022	13.5	-87.24%
2021	106	-68.96%
2020	342	278.58%
2019	90.2	10.04%
2018	82.0	-46.14%
2017	152	-8.1%
2016	166	13.12%
2015	146	-2.39%
2014	150	110.2%
2013	71.4	-91.97%
2012	888	1238.34%
2011	66.4	-34.46%
2010	101	36.92%
2009	74.0	164.13%
2008	28.0	210.09%
2007	9.03	75.44%
2006	5.15	-32.86%
2005	7.67	-80.38%
2004	39.1	15.37%
2003	33.9	-40.03%
2002	56.5	-83.96%
2001	352

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
ORIC Pharmaceuticals ORIC	N/A	N/A	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Lineage Cell Therapeutics (LCTX)

P/S ratio as of November 2024 (TTM): 27.0